Neurogene: Stock Soars On FDA Designation For Rett Gene Therapy - I'd Remain Cautious
Source: SeekingAlpha
2026-02-27 15:32:50 ET
Breaking News - Neurogene snags Breakthrough Therapy Designation For Gene Therapy
Read the full article on Seeking Alpha
For further details see:
Neurogene: Stock Soars On FDA Designation For Rett Gene Therapy - I'd Remain Cautious
Neurogene Inc.
NASDAQ: NGNE
NGNE Trading
-4.42% G/L:
$22.71 Last:
29,662 Volume:
$22.55 Open:
NGNE Latest News
February 27, 2026 09:00:45 am
Neurogene Shares Rally on FDA Breakthrough Therapy Designation for Rett Syndrome Therapy
February 26, 2026 04:01:00 pm
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
NGNE Stock Data
$263,326,600
13,686,787
0.57%
9
N/A
Pharmaceuticals
Healthcare
US
New York
